Incyte Pipeline

November 19, 2015

INCYTE Pipeline

  1. Patients with intermediate or high-risk myelofibrosis
  2. Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea
  3. Worldwide rights to baricitinib licensed to Lilly
  4. DN = Diabetic nephropathy
  5. GBM = Glioblastoma multiforme
  6. Worldwide rights to capmatinib licensed to Novartis